The company is seeking to develop a monoclonal antibody with antiplatelet activity as a first line emergency treatment of stroke.Download the PDF
Paris, January 26th, 2015, Acticor Biotech, a biotech company dedicated to the development of an emergency treatment of ischemic stroke, announced today the successful closing of its first capital increase for a total of €590,000. This amount, raised from investors of the crowdfunding platform Anaxago and Business Angels, enables the young Inserm (French National Institute of Health and Medical Research) spin-off to launch the development of its product. The drug candidate ACT017 is a humanized antibody (Fab) directed against a new target of major interest for the treatment of cerebral stroke, the platelet glycoprotein VI (GPVI).
With two thirds of the capital increase raised with the equity crowdfunding platform Anaxago, Acticor Biotech becomes one of the first companies to successfully raise equity crowd-funds for therapeutic biotechnologies. The level of investors interest in this project demonstrates the strong will of participants to support the development of innovative solutions addressing major public health concerns.
Dr Gilles Avenard, CEO of Acticor Biotech, is delighted by this success. “It is a first step for Acticor that will enable us to design the best production system to start the development of our lead compound ACT017. We are thrilled to embark crowdfunding investors altogether with Business Angels experienced in the healthcare sector, and a research association that specialises in this specific medical field.”
This capital increase takes place as Acticor just signed an agreement with Genopole that will allow the company to join the biocluster and benefit from services to support its structural development and growth.
For the crowdfunding platform Anaxago, the funding of a first biotech startup further validates the business model for the healthcare sector. “The platform members have been very responsive to Acticor Biotech’s mission and massively supported the campaign” comments Joachim Dupont, founder and CEO of Anaxago.
About Acticor Biotech
Acticor Biotech is an Inserm spin-off. Founded in late 2013, the company’s mission is primarily to develop the anti-GPVI antibody as a platelet-aggregation inhibitor for acute thrombotic pathologies. Acticor Biotech’s project is based on scientific research from two Inserm units and was lead by Drs Martine Jandrot-Perrus (U1148) and Christian Gachet (U949), and by Pr. Philippe Billiald from the Institut Paris-Sud d’Innovation Thérapeutique.
Anaxago was founded in 2012 and quickly became the French leader for equity crowdfunding platform. So far, Anaxago members successfully invested more than €12 millions in 30 companies.
Contact: Caroline Lamaud I 06.61.39.89.07 I email@example.com
France’s leading biocluster: Genopole unites 80 biotech companies, 19 research laboratories, 21 technical platforms, and higher education training programs (University of Évry-Val-d’Essonne). Genopole directly employs 2,245 people, including 800 researchers. Since the launch of the biocluster, the site’s businesses have raised €368 million in capital. Genopole is funded mainly by the Ile-de-France Regional Council (30%), the Essonne General Council (26.5%) and the French State (15.7%).
Contact: firstname.lastname@example.org / Tel: +33 970 446 901
Acticor Biotech, Bâtiment Inserm U1148, Hôpital Bichat secteur Claude Bernard,
46 rue Henri Huchard, 75877 Paris Cedex 18, France
Read next in 'Press Releases'
- ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS
- Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital
- Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer
- Acticor Biotech first-in-human clinical trial in healthy volunteers
- Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum